An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has announced that its subsidiary, Shanghai JMT-BIO Technology Co., Ltd., has received approval from the U.S. FDA to conduct clinical trials for its antibody drug JMT203 in the United States. This drug targets cancer cachexia, a condition with no current GDF15 or GFRAL-targeted treatments available globally. The approval marks a significant step in CSPC’s efforts to provide an effective treatment for cancer cachexia, potentially improving the quality of life for tumor patients and enhancing the company’s position in the pharmaceutical industry.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-based company operating in the pharmaceutical industry, focusing on the development and production of innovative drugs. The company is known for its work in biopharmaceuticals and has a market focus on addressing unmet medical needs.
YTD Price Performance: 8.47%
Average Trading Volume: 29,601
Technical Sentiment Signal: Buy
Current Market Cap: $8.26B
For an in-depth examination of 1093 stock, go to TipRanks’ Stock Analysis page.